Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 7712 results

  1. Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)

    This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.

    NICE guideline
    Published
    23 May 2019
    View recommendations

    Sections for NG132

  2. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

    This guideline sets out an antimicrobial prescribing strategy for hospital-acquired pneumonia. It does not cover ventilator-associated pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    16 September 2019
    View recommendations

    Sections for NG139

  3. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.

    NICE guideline
    Published
    19 August 2021
    View recommendations

    Sections for NG201

  4. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults (NG215)

    This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.

    NICE guideline
    Published
    20 April 2022
    View recommendations

    Sections for NG215

  5. Maternal and child nutrition (PH11)

    This guideline covers the nutrition of pregnant women, including women who are planning to become pregnant, mothers and other carers of children aged under 5 and their children. In particular, it aims to address disparities in the nutrition of low-income and other disadvantaged groups compared with the general population.

    Public health guideline
    Last updated
    1 November 2014
    View recommendations

    Sections for PH11

  6. Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

    In development [GID-TA11384] Expected publication date: 28 January 2025

    Technology appraisal guidance
    In development

  7. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  8. Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

    In development [GID-TA10611] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  9. Systemic lupus erythematosus

    All NICE products on systemic lupus erythematosus. Includes any guidance.

    Topic page

  10. Complications of cancer

    All NICE products on complications of cancer. Includes any guidance, advice and quality standards.

    Topic page

  11. Endometrial cancers

    All NICE products on endometrial cancers. Includes any guidance.

    Topic page

  12. Brain cancers

    All NICE products on brain cancers. Includes any guidance, advice and quality standards.

    Topic page

  13. Breast cancer

    All NICE products on breast cancer. Includes any guidance, advice and quality standards.

    Topic page

  14. Genomic biomarker-based cancer treatments

    All NICE products on genomic biomarker-based cancer treatments. Includes any guidance.

    Topic page

  15. Colorectal cancer

    All NICE products on colorectal cancer. Includes any guidance, advice and quality standards.

    Topic page